Evidence map›Paper›PMID 37000790›Full record

ArticlePloS one2023

Mapping EQ5D utilities from forced vital capacity and diffusing capacity in fibrotic interstitial lung disease.

Alyson W Wong, Huiying Sun, Ingrid A Cox, Jolene H Fisher, Nasreen Khalil, Kerri A Johannson, Veronica Marcoux, Deborah Assayag, Helene Manganas, Martin Kolb and 11 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 14 institutions in 2 countries.

Alyson W WongDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0003-4910-1948
Huiying SunCentre for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada.
Ingrid A CoxMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
Jolene H FisherDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Nasreen KhalilDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Kerri A JohannsonDepartment of Medicine, University of Calgary, Calgary, AB, Canada.
Veronica MarcouxDepartment of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Deborah AssayagDepartment of Medicine, McGill University, Montreal, Quebec, Canada.
Helene ManganasDépartement de Médecine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Martin KolbDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
Andrew J PalmerMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
Barbara de GraaffMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
E Haydn WaltersSchool of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
Peter HopkinsLung Transplant Unit, The Prince Charles Hospital, Brisbane, Australia.
Christopher ZappalaDept of Thoracic Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.
Nicole S GohDept of Respiratory and Sleep Medicine, Austin Hospital, Heidelberg, Australia.
Yuben MoodleyDepartment of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Australia.
Vidya NavaratnamLung Transplant Unit, The Prince Charles Hospital, Brisbane, Australia.
Tamera J CorteDepartment of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Christopher J RyersonDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Wei ZhangCentre for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada.
University of British Columbia · CAUniversity of Tasmania · AUPrince Charles Hospital · AUAustin Hospital · AUCentre for Advancing Health Outcomes · CACentre Hospitalier de l’Université de Montréal · CAFiona Stanley Hospital · AUMcGill University · CAMcMaster University · CARoyal Brisbane and Women's Hospital · AUThe University of Sydney · AUUniversity of Calgary · CAUniversity of Saskatchewan · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesFibrotic interstitial lung disease (ILD) includes a large group of conditions that lead to scarring of the lungs. The lack of available 5-level EuroQol 5D (EQ5D) data has limited the ability to conduct economic evaluations in ILD. The purpose of this study was to develop and validate a mapping algorithm that predicts EQ5D utilities from commonly collected pulmonary function measurements (forced vital capacity [FVC] and diffusing capacity of the lung for carbon monoxide [DLCO]) in fibrotic ILDs.

methodsEQ5D utility and pulmonary function measurements from the Canadian Registry for Pulmonary Fibrosis were included. Ordinary least squares (OLS), beta regression, two-part, and tobit models were used to map EQ5D utilities from FVC or DLCO. Model performance was assessed by comparing the predicted and observed utilities. Subgroup analyses were also conducted to test how well models performed across different patient characteristics. The models were then externally validated in the Australian Idiopathic Pulmonary Fibrosis Registry.

resultsThe OLS model performed as well as other more complex models (root mean squared error: 0.17 for FVC and 0.16 for DLCO). As with the other models, the OLS algorithm performed well across the different subgroups (except for EQ5D utilities < 0.5) and in the external validation cohort.

conclusionWe developed a mapping algorithm that predicts EQ5D utilities from FVC and DLCO, with the intent that this algorithm can be applied to clinical trial populations and real-world cohorts that have not prioritized collection of health-related utilities. The mapping algorithm can be used in future economic evaluations of potential ILD therapies.

Indexed as

Idiopathic Pulmonary FibrosisLung Diseases, InterstitialAustraliaCanadaHumansLungVital Capacity

Identifiers

PMID37000790
PMCPMC10065299
OpenAlexW4362465771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.